miR ‐181a overexpression predicts the poor treatment response and early‐progression of serous ovarian cancer patients

2020 ◽  
Vol 147 (12) ◽  
pp. 3560-3573
Author(s):  
Konstantina Panoutsopoulou ◽  
Margaritis Avgeris ◽  
Paraskevi Magkou ◽  
Konstantinos Mavridis ◽  
Tobias Dreyer ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Treatment Response ◽  
Cancer Patients ◽  
Serous Ovarian Cancer ◽  
The Poor ◽  
Early Progression ◽  
Poor Treatment ◽  
Poor Treatment Response

P175 POOR TREATMENT RESPONSE IN LUNG CANCER PATIENTS WITH HIGH RISK OF UNDERNUTRITION

2009 ◽  
Vol 4 (2) ◽  
pp. 99
Author(s):  
M. Tomiska ◽  
M. Tomiskova ◽  
P. Illa ◽  
L. Buresova ◽  
J. Skrickova
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Treatment Response ◽  
Cancer Patients ◽  
Lung Cancer Patients ◽  
Poor Treatment ◽  
Poor Treatment Response

Identification of Genes and Genetic Variants Associated with Poor Treatment Response in Patients with Prostate Cancer

2014 ◽  
Author(s):  
Lisa A. Cannon-Albright ◽  
Neeraj Agarwal ◽  
Craig Teerlink
Keyword(s):  
Prostate Cancer ◽  
Treatment Response ◽  
Genetic Variants ◽  
Poor Treatment ◽  
Poor Treatment Response

Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients

2021 ◽  
Author(s):  
Anna P. Sokolenko ◽  
Tatiana V. Gorodnova ◽  
Ilya V. Bizin ◽  
Ekaterina Sh. Kuligina ◽  
Khristina B. Kotiv ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
High Grade ◽  
Serous Ovarian Cancer

scholarly journals Roles of E-cadherin and Cyclooxygenase Enzymes in Predicting Different Survival Patterns of Optimally Cytoreduced Serous Ovarian Cancer Patients

2012 ◽  
Vol 13 (11) ◽  
pp. 5715-5719 ◽  
Author(s):  
Salih Taskin ◽  
Ilkkan Dunder ◽  
Ebru Erol ◽  
Elif Aylin Taskin ◽  
Saba Kiremitci ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Serous Ovarian Cancer ◽  
Survival Patterns ◽  
E Cadherin

scholarly journals Knowledge and Anxiety Related to Hereditary Ovarian Cancer in Serous Ovarian Cancer Patients

2019 ◽  
Vol 25 (4) ◽  
pp. 365 ◽  
Author(s):  
Sang Hee Lee ◽  
Hyangkyu Lee ◽  
Myong Cheol Lim ◽  
Sue Kim
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Serous Ovarian Cancer ◽  
Hereditary Ovarian Cancer

scholarly journals Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia

2017 ◽  
Vol 137 (1) ◽  
pp. 39-46 ◽  
Author(s):  
R. McCutcheon ◽  
K. Beck ◽  
E. D'Ambrosio ◽  
J. Donocik ◽  
C. Gobjila ◽  
...  
Keyword(s):  
Treatment Response ◽  
Plasma Levels ◽  
Poor Treatment ◽  
Poor Treatment Response

Classification of serous ovarian cancer patients with suboptimal surgical outcomes by clinical molecular features

2018 ◽  
Vol 149 ◽  
pp. 179
Author(s):  
A.M. Newtson ◽  
M.E. McDonald ◽  
H.D. Reyes ◽  
Y.A. Lyons ◽  
M.J. Goodheart ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Surgical Outcomes ◽  
Serous Ovarian Cancer ◽  
Molecular Features

scholarly journals Quantitative Analysis of Retinal Microvascular Perfusion and Novel Biomarkers of the Treatment Response in Diabetic Macular Edema

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Young Gun Park ◽  
Young-Hoon Park
Keyword(s):  
Macular Edema ◽  
Treatment Response ◽  
Subgroup Analysis ◽  
Poor Response ◽  
Flow Ratio ◽  
The Poor ◽  
Poor Treatment ◽  
Capillary Plexus ◽  
Intravitreal Dexamethasone ◽  
Response Group

Purpose. We aimed to assess the changes of retinal microvascular parameters using optical coherence tomography angiography (OCTA) between diabetes macular edema (DME) and controls. We assessed the changes between the baseline microvascular parameters and final treatment response in patients with DME, initially treated with intravitreal dexamethasone (DEX) implant followed by antivascular endothelial growth factor (VEGF) injections on an as-needed basis. Methods. This retrospective study included 90 DME patients and 24 healthy control subjects. All subjects had their best-corrected visual acuity (BCVA) and central macular thickness (CMT) measured at baseline and after 12 months. Vessel density (VD) in the superficial capillary plexus (SCP) and deep capillary plexus (DCP) and the deep/superficial flow ratio at baseline were analyzed. A subgroup analysis was used to compare the treatment response. A poor-response group was defined by five or more retreatments at 12 months. Results. BCVA and CMT showed a significant improvement at 12 months (all p < 0.001 ). The VD in the whole and parafoveal areas of the DCP was significantly reduced in DME patients compared to that in controls (all p < 0.05 ). The DCP/SCP flow ratio was also significantly reduced in the DME group ( 1.08 ± 0.03 vs. 1.05 ± 0.02 , p = 0.001 ). In the subgroup analysis, the VD in the foveal and whole DCP areas was significantly lower in the poor-response group than that in the good-response group ( p = 0.043 and p = 0.048 , respectively). The DCP/SCP flow ratio was also significantly lower in the poor-response group ( p = 0.011 ). Conclusion. DME correlated with significant retinal microvascular impairment in the DCP. A decreased DCP/SCP flow ratio was observed in patients with DME that exhibited a poor treatment response. Retinal microvascular parameters could predict the treatment response in DME and help optimize clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document